Aquinox Pharmaceuticals, Inc. (AQXP) financial statements (2020 and earlier)

Company profile

Business Address SUITE 360 - 1616 EASTLAKE AVE EAST
SEATTLE, WA 98102
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments143771081037439
Cash and cash equivalents1437752324015
Short-term investments  56713524
Other undisclosed current assets101000
Total current assets:144771091037539
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment201100
Long-term investments and receivables   50382
Long-term investments   50382
Intangible assets, net (including goodwill)1     
Intangible assets, net (excluding goodwill)1     
Other noncurrent assets     0
Other undisclosed noncurrent assets001   
Total noncurrent assets:30251392
TOTAL ASSETS:1477811015411341
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:318835
Accounts payable216721
Accrued liabilities00 000
Employee-related liabilities102110
Other undisclosed accounts payable and accrued liabilities     4
Debt1 000 
Other liabilities  100 
Other undisclosed current liabilities14312 
Total current liabilities:55111055
Noncurrent Liabilities
Long-term debt and lease obligation1     
Finance lease, liability0
Operating lease, liability0
Liabilities, other than long-term debt 00000
Other liabilities 0000 
Derivative instruments and hedges, liabilities     0
Total noncurrent liabilities:100000
Total liabilities:55111055
Stockholders' equity
Stockholders' equity attributable to parent142739914510836
Common stock     0
Additional paid in capital441303297293220126
Accumulated other comprehensive loss  (0)(0)(0)(0)
Accumulated deficit(300)(230)(199)(148)(111)(89)
Total stockholders' equity:142739914510836
TOTAL LIABILITIES AND EQUITY:1477811015411341

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit: 25    
Operating expenses(71)(58)(51)(38)(21)(22)
Operating loss:(71)(33)(51)(38)(21)(22)
Nonoperating income (expense)2111(1)(2)
Investment income, nonoperating    (0)1
Other nonoperating income (expense)2111(0)(0)
Interest and debt expense(0)(0)(0)(0) (0)
Other undisclosed income from continuing operations before equity method investments, income taxes0000 0
Loss from continuing operations before income taxes:(69)(32)(50)(37)(22)(24)
Income tax benefit     0
Net loss attributable to parent:(69)(32)(50)(37)(22)(24)
Preferred stock dividends and other adjustments     (0)
Other undisclosed net income available to common stockholders, basic     0
Net loss available to common stockholders, diluted:(69)(32)(50)(37)(22)(24)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(69)(32)(50)(37)(22)(24)
Comprehensive loss:(69)(32)(50)(37)(22)(24)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 000(0)(0)
Comprehensive loss, net of tax, attributable to parent:(69)(32)(50)(37)(22)(24)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: